Table 2 Subgroup analysis for the risk of vaccination with SLE
From: Vaccination and the risk of systemic lupus erythematosus: a meta-analysis of observational studies
Subgroups | Included studies | OR (95% CI) | Heterogeneity | |
|---|---|---|---|---|
I 2 (%) | P-value | |||
Region | ||||
North America | 7 | 1.87 (0.99, 3.52) | 73.2 | 0.053 |
Europe | 7 | 0.96 (0.84, 1.10) | 0.0 | 0.551 |
Asia | 3 | 0.79 (0.30, 2.07) | 93.9 | 0.628 |
Observation time | ||||
≥ 180 days | 8 | 1.09 (0.89, 1.33) | 0.0 | 0.408 |
< 180 days | 8 | 1.13 (0.68, 1.87) | 87.3 | 0.634 |
Study type | Â | Â | Â | Â |
Case-control study | 7 | 1.84 (1.03, 3.31) | 75.9 | 0.041 |
Cohort study | 10 | 0.85 (0.65, 1.11) | 68.3 | 0.243 |